Transcript 25 s
BioRet’s Personal Bio Assistant: on-the-spot analysis for on-the-spot decisions BioRet, 1 Rue du Parc Foulon, Villebon 91140, France. T: +331 60 10 04 37 F: +331 60 10 88 95 www.bioret.com Email : [email protected] [email protected] April 2004 1/14 New Paradigm for the Point-of Care Analysis BioRet is developing a portable diagnostic device to answer unmet needs in major market segments Detection of different antibiotics in milk Traces of nuts in food Monitoring of health parameters Accurate and reliable Drugs of Abuse tests Toxins detection in the enviroment Why? Today biochip readers are specifically designed for research purposes They are not portable, difficult to handle and expensive To address these market needs, BioRet is developing a reliable yet low cost solution consisting of: A reader: The Personal Bio Assistant Dedicated biochips: The BioMatrix April 2004 040317_QUEB_BioRet 2 / 10 2/14 Company Mission BioRet is developing a portable biochip reader and associated biochips to be used for on-site testing The Personal Bio Assistant: PBA The BioMatrix PBA April 2004 3/14 On-the-spot bio-analyses Portable reader “PBA” Dedicated biochips “BioMatrix” Reliable results High on-site sensitivity High dynamic reading of signals Portability Easy sample preparation Affordable Adaptableto hundreds of dedicated multiplex analyses Remote interfacing with databases April 2004 040317_QUEB_BioRet 4 / 10 4/14 Company profile Company: Limited Registered in March 2002 3 employees Key partnerships: Public: CNRS (ISV & IEF) R&D: Kikkoman (Soy sauce company) Supported by: Genopole, ANVAR, BIOCritt, IDFI, IXCORE April 2004 5/14 Team • J Pollard, Founder Chief Executive Officer ENSAM Engineer. PhD in Metallurgy University of Paris 1965. SEP Stanford Business School 1979 • B Rébillé, Co-founder Business development Director BS NYU (Stern) 1989. MBA HEC 1993 • S Brown, Biologist, Co-founder & Scientific Board Director CNRS Plant Science Institute BAgSc University of Adelaide 1970, PhD 1980 • E Belhaire, Electronician , Co-founder & Scientific Board Group leader CNRS Institut d’Electronique Fondamentale École Normale Supérieure "Agrégation de Physique Appliquée" 1987. PhD Physics University of Paris 1992 • F Képès, Biologist , Co-founder & Scientific Board Director CNRS Epigenomics Institute École Normale Supérieure, 1980; PhD Biology 1985. • C Kluge, Biologist & Protein biochemist PhD Biology Bielefeld University 2002. • S Lévy, Advisor Ingénieur Chimiste de l’Ecole de Chimie Physique Electronique de Lyon. MBA HEC 1993 April 2004 6/14 Key Markets PBA’s potential markets Healthcare Blood analysis Urine analysis Others… Environment Soil pollution Waste water Others… Food industry Microbiological testing Toxins Others… In-vitro diagnostic markets April 2004 7/14 A Wide Range of Applications for the PBA Food safety: surveillance of raw material and processed products, toxins, bacteria, GMOs, pesticides, animal health.. Personalised medicine: monitoring of medical treatment, observation of body parameters, allergies, cardiac markers, drug control, pathogen diagnostic.. Environmental control: Bio-defence, water April 2004 8/14 Innovative Technology for the PBA To ensure the portability and exact results of the PBA, BioRet uses an innovative, miniaturised, optoelectronic sensor known as “Intelligent Retina” Incident light Intelligent retina Pixel sample Processing area Photosensitive area The Intelligent Retina ensures a highly sensitive acquisition with no readout noise Active, self-adaptive pixels allow a biochip reading with an ultra-high dynamic In situ highly parallel powerful image processing The Intelligent Retina is protected by 8 patents valid until 2009 and 2019 April 2004 9/14 The BioMatrix: a BioChip for chemiluminescent detetction BioRet’s biochip packaging format: The BioMatrix will allow a parallelisation of bio tests Easily adaptable to current production lines Low-complexity up to 256 spots Internal standards Including positive,negative controls and quantification standarts Quantitative analysis Antibodies in replicates in different concentrations to ensure linear binding Square shape 4 by 4 mm Chemiluminescence detection no need for space-filling excitation devices like lasers April 2004 hv 10/14 The time-resolved capture mode of the Intelligent Retina increases the sensitivity of detection Example of morphine-detection with a MAB 5 000 ng/ml 500 ng/ml 50 ng/ml 35 375 photons Saturation 5 000 photons Capture 786 photons Blindness CCD-camera capture emulation •Uniform recording time 25 s •Detection @ 300 ng/ml 25 s 5 000 photons Capture 25 s 25 s 5 000 photons Capture 5 000 photons Capture 100 µm Intelligent Retina capture emulation •Automatic adaption of recording times related to local intensities 3s 25 s 160 s •Detection @ 40 ng/ml • Monoclonal antibodies against morphine were spotted in a concentration of 500 µg/ ml on BioRet’s BioMatrix. • Incubation with peroxidase-coupled morphine in 3 different concentrations. Incubation with luminol substrate. • Photon-emissions were recorded using a photon-counting set-up from Institut Pasteur. April 2004 11/14 Detection of Staphyllococcus Protein A with the BioMatrix® (Collaboration with Kikkoman) Test of new chemiluminescent substrates from Kikkoman on the BioMatrix for the parallel detection of Staphyllococcus and Salmonella Down to one part per million can be detected (in line with current requirements) 1 ug Protein A April 2004 500 ng Protein A 100 ng Protein A 1 ng Protein A 12/14 BioMatrix & PBA Multiplex Analyses Miniaturized Reliable Economical for reagents Disposable & low cost solution Hundreds of dedicated applications April 2004 040317_QUEB_BioRet 13 / 10 13/14 Interested organizations Kikkoman Food safety October 03 French Safety Traffic Agency Drug of abuse February 04 National Institute of Agronomy Medication & Food safety March 04 French Food Security Agency Food safety March 04 French Milk Professional Organization Milk safety March 04 April 2004 14/14